Published : 16 Jun 2026
Aagami is proud to announce a New Client Win. We have been officially appointed by a prominent, rapidly growing global pharmaceutical company to spearhead the outlicensing and strategic partnering for their highly anticipated biosimilar portfolio in the Japanese and South Korean markets.
Our client's robust pipeline includes high-quality biosimilars for major blockbuster biologics such as:
Securing strong strategic partnerships in Japan and South Korea is a critical step in maximizing the global footprint and patient access to these vital immunology and oncology therapeutics.
Aagami was chosen for this mandate based on our extensive, deep-rooted network and our proven track record of successful deal-making across the Asia-Pacific life sciences ecosystem.
Our team shall soon initiate outreach and expects strong interest from leading regional pharmaceutical companies looking to expand their biologic portfolios with these high-value assets.
For more information on these specific out-licensing opportunities, or to discuss a potential strategic partnership, please contact us at action@aagami.com .